DIVA Laboratories Ltd (4153) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DIVA Laboratories Ltd (4153) has a cash flow conversion efficiency ratio of 0.005x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$5.57 Million ≈ $175.45K USD) by net assets (NT$1.03 Billion ≈ $32.42 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check DIVA Laboratories Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.
DIVA Laboratories Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how DIVA Laboratories Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. See DIVA Laboratories Ltd net assets for net asset value and shareholders' equity analysis.
DIVA Laboratories Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DIVA Laboratories Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Prescient Therapeutics Ltd
AU:PTX
|
-0.386x |
|
Zee Media Corporation Limited
NSE:ZEEMEDIA
|
0.288x |
|
Great Computer
TWO:8047
|
0.057x |
|
Gold Hydrogen Ltd
AU:GHY
|
-0.023x |
|
Flanigans Enterprises Inc
NYSE MKT:BDL
|
0.062x |
|
KUYA SILVER CORP.
F:6MR1
|
N/A |
|
IXAQF
NASDAQ:IXAQF
|
0.078x |
|
MCE Holdings Bhd
KLSE:7004
|
-0.006x |
Annual Cash Flow Conversion Efficiency for DIVA Laboratories Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of DIVA Laboratories Ltd from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see 4153 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.03 Billion ≈ $32.42 Million |
NT$20.77 Million ≈ $654.34K |
0.020x | -82.70% |
| 2024-12-31 | NT$1.06 Billion ≈ $33.25 Million |
NT$123.14 Million ≈ $3.88 Million |
0.117x | -52.36% |
| 2023-12-31 | NT$1.03 Billion ≈ $32.54 Million |
NT$252.91 Million ≈ $7.97 Million |
0.245x | +240.01% |
| 2022-12-31 | NT$1.02 Billion ≈ $32.02 Million |
NT$73.19 Million ≈ $2.31 Million |
0.072x | +723.74% |
| 2021-12-31 | NT$986.42 Million ≈ $31.08 Million |
NT$-11.39 Million ≈ $-358.85K |
-0.012x | +31.40% |
| 2020-12-31 | NT$988.89 Million ≈ $31.16 Million |
NT$-16.64 Million ≈ $-524.38K |
-0.017x | -136.22% |
| 2019-12-31 | NT$1.13 Billion ≈ $35.70 Million |
NT$52.66 Million ≈ $1.66 Million |
0.046x | -36.04% |
| 2018-12-31 | NT$1.18 Billion ≈ $37.30 Million |
NT$86.02 Million ≈ $2.71 Million |
0.073x | +41.41% |
| 2017-12-31 | NT$806.75 Million ≈ $25.42 Million |
NT$41.45 Million ≈ $1.31 Million |
0.051x | -- |
About DIVA Laboratories Ltd
DIVA Laboratories, Ltd. engages in the development, manufacture, and sale of medical equipment and computer related devices worldwide. The company provides endo/surgical displays, a static and dynamic image for hybrid and integrated ORs applications; color and mono displays for radiology and medical imaging applications; touch displays/human machine interface products; medical and industrial case… Read more